Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20210
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChristou, L.en
dc.contributor.authorHatzimichael, E.en
dc.contributor.authorChaidos, A.en
dc.contributor.authorTsiara, S.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:05:33Z-
dc.date.available2015-11-24T19:05:33Z-
dc.identifier.issn0902-4441-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20210-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectCardiomyopathies/chemically induced/prevention & controlen
dc.subjectDexamethasone/administration & dosage/adverse effectsen
dc.subjectDoxorubicin/administration & dosage/adverse effectsen
dc.subjectDrug Carriersen
dc.subjectDrug Evaluationen
dc.subjectElectrocardiographyen
dc.subjectFatal Outcomeen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLeukemia, Plasma Cell/blood/*drug therapyen
dc.subjectLiposomesen
dc.subjectMiddle Ageden
dc.subjectRemission Inductionen
dc.subjectSafetyen
dc.subjectTreatment Outcomeen
dc.subjectVincristine/administration & dosage/adverse effectsen
dc.titleTreatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasoneen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11553267-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1034/j.1600-0609.2001.067001051.x/asset/j.1600-0609.2001.067001051.x.pdf?v=1&t=h2bon8qw&s=f016733b509474ed5f6d06276774ff018b7504c9-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2001-
heal.abstractPrimary plasma cell (PCL) leukemia is a rare lymphoproliferative disorder characterized by a malignant proliferation of plasma cells in the bone marrow and peripheral blood. Survival with standard therapy using melphalan is very poor. Doxorubicin encapsulated with liposomes has less cardiotoxicity, is at least as efficient and has fewer side effects than conventional doxorubicin. Two female patients (69 and 54 yr old) with primary PCL are described in this study. They both received a modified form of VAD (vincristine, doxorubicin and dexamethasone), a regimen which includes liposomal doxorubicin (40 mg/m2 for 1 d), vincristine (2 mg for 1 d) and dexamethasone 40 mg per os on days 1-4, 9-12 and 17-20. A disease evaluation of the first patient after six courses of the modified \VAD regimen showed no plasma cells in the peripheral blood, a decrease in the serum M protein level and a plasma cell infiltration in the bone marrow of less than 5%. The patient died from a cardiac episode 24 months post-diagnosis, while she was in complete hematological remission. The second patient also exhibited good tolerance to liposomal doxorubicin with no side effects, achieved complete haematological remission and remains in good condition 7 months after the last VAD administration. These results suggest that this modified form of VAD regimen also seems to work in PCL and is well tolerated with no side effects.en
heal.journalNameEur J Haematolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Christou-2001-Treatment of plasma.pdf60.19 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons